Covid-19 vaccine interchangeability study
Phase 4
- Registration Number
- CTRI/2022/06/043447
- Lead Sponsor
- Indian Council of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
healthy
Exclusion Criteria
children less than 18 years
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Antibody titers against Spike protein after interchangeability of the study vaccines at baseline, 28 days of first and second dose, 6 months and 1 year. <br/ ><br>2. Incidence of mild, moderate and serious adverse events rate of the Covid-19 vaccines after interchangeability <br/ ><br>3. Breakthrough infection rate of the Covid-19 vaccines (Covishield/Covaxin/Sputnik V) after interchangeability.Timepoint: At at baseline, 28 days of first and second dose, 6 months and 1 year.
- Secondary Outcome Measures
Name Time Method eutralizing antibody and celle mediated immune response after interchangeability of covid-19 vaccinesTimepoint: at baseline, 28 days of first and second dose, 6 months and 1 year.